Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab

9 Sept 2021

Abstract excerpt

To advance the use of circulating tumor DNA (ctDNA) applications, their broad clinical validity must be tested in different treatment settings, including targeted therapies. Using the prespecified longitudinal systematic collection of plasma samples in the phase 1/2a LYM1002 trial (registered on www.clinicaltrials.gov as NCT02329847), we tested the clinical validity of ctDNA for baseline mutation profiling,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Chronic Lymphocytic Leukemia Research
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34500472
DOI: 10.1182/bloodadvances.2021004528

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumabPMID 34500472Read ↗

Clinical use of circulating tumor DNA analysis in patients with lymphomaSemantic proximity Read ↗

Circulating tumor DNA as a powerful tool in diagnostics and treatment outcome prediction - focus on large B-cell lymphomas and follicular lymphomas.Semantic proximity Read ↗

Circulating Tumor DNA Reflects Histologic and Clinical Characteristics of Various Lymphoma Subtypes.Semantic proximity Read ↗

Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational researchSemantic proximity Read ↗

Circulating tumor DNA assisting lymphoma genetic feature profiling and identification.Semantic proximity Read ↗

Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.Semantic proximity Read ↗

Circulating Tumor DNA as a Biomarker of Treatment Response and Minimal Residual Disease in Diffuse Large B-Cell Lymphoma: A Literature ReviewSemantic proximity Read ↗

Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma.Semantic proximity Read ↗

Plasma circulating tumour DNA is a better source for diagnosis and mutational analysis of IVLBCL than tissue DNA.Semantic proximity Read ↗

Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution.Semantic proximity Read ↗

Circulating tumour DNA in B‐cell lymphomas: current state and future prospectsSemantic proximity Read ↗

[Progression and application of circulating tumor DNA in lymphoma].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.